Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bunamiodyl is an iodinated organic compound formerly used as an oral radiopaque contrast medium for cholecystography and cholangiography. It functions by being absorbed from the gastrointestinal tract and excreted into the bile, allowing for X-ray visualization of the gallbladder and biliary ducts. However, its use was largely discontinued in the mid-1960s due to reports of severe nephrotoxicity, including fatal acute renal failure (anuria), particularly in patients with pre-existing hepatic impairment or when administered in high doses. Mechanistically, it competes with bilirubin and other organic anions for binding to hepatic cytoplasmic proteins (specifically the Z fraction), which can lead to transient hyperbilirubinemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bunamiodyl.